AAPS PharmSciTech

, 10:1085 | Cite as

Development and Evaluation of Buccal Bioadhesive Tablet of an Anti-emetic Agent Ondansetron

  • Nisreen Hassan
  • R. K. Khar
  • Mushir Ali
  • Javed Ali
Research Article

Abstract

The aim of the present study was to develop and evaluate a buccal adhesive tablet containing ondansetron hydrochloride (OH). Special punches and dies were fabricated and used while preparing buccal adhesive tablets. The tablets were prepared using carbopol (CP 934), sodium alginate, sodium carboxymethylcellulose low viscosity (SCMC LV), and hydroxypropylmethylcellulose (HPMC 15cps) as mucoadhsive polymers to impart mucoadhesion and ethyl cellulose to act as an impermeable backing layer. The formulations were prepared by direct compression and characterized by different parameters such as weight uniformity, content uniformity, thickness, hardness, swelling index, in vitro drug release studies, mucoadhesive strength, and ex vivo permeation study. As compared with the optimized formulation composed of OH—5 mg, CP 934—30 mg, SCMC LV—165 mg, PEG 6000—40 mg, lactose—5 mg, magnesium stearate—1.5 mg, and aspartame—2 mg, which gave the maximum release (88.15%), non-bitter (OH) that form namely ondansetron base and complexed ondansetron was used in order to make the selected formulation acceptable to human. The result of the in vitro release studies and permeation studies through bovine buccal mucosa revealed that complexed ondansetron gave the maximum release and permeation. The stability of drug in the optimized adhesive tablet was tested for 6 h in natural human saliva; both the drug and device were found to be stable in natural human saliva. Thus, buccal adhesive tablet of ondansetron could be an alternative route to bypass the hepatic first-pass metabolism and to improve the bioavailability of (OH).

Key words

buccal adhesive tablet buccal delivery mucoadhesion ondansetron hydrochloride optimized formula 

References

  1. 1.
    Lachaine J, Laurier C, Langleben A, Vaillant L. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. J Oncol Hema. 1999;32:105–12.Google Scholar
  2. 2.
    Mohan KC, Ravikumar K. Ondansetron hydrochloride: a competitive serotonin 5-HT3 receptor blocker. Acta Cryst Sect C Cryst Struct Comm. 1995;C51:2627–9.CrossRefGoogle Scholar
  3. 3.
    Milap PhDNC, Leanna HN, John PhDK. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. Clinical Therapeutics. 1996;18:466–76.CrossRefGoogle Scholar
  4. 4.
    Alur HH, Pather SI, Mitra AK, Johnston TP. Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel natural mucoadhesive gum as excipients in buccal tablets. Int J Pharm. 1999;188:1–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Salem II, Lopez JMR, Galan AC. Ondansetron hydrochloride. In: Brittan HG, Academic Press an Imprint of Elsevier, editors. Analytical profiles of drug substances and excipients, vol. 27. California: San Diego; 2001. p. 301–339.CrossRefGoogle Scholar
  6. 6.
    Miller NS, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Del. 2005;57:1666–91.CrossRefGoogle Scholar
  7. 7.
    Jain CB, Aungs J, Adeyeye MC. Development and in vivo evaluation of buccal tablets prepared using danazol-, sulfobutylether 7ß-cyclodextrin (SBE7) complexes. J Pharm Sci. 2002;91:1659–68.CrossRefPubMedGoogle Scholar
  8. 8.
    Patel VM, Prajapati BG, Patel MM. Formulation, evaluation, and comparison of bilayered and multilayered mucoadhesive buccal devices of propranolol hydrochloride. AAPS PharmSciTech. 2007;8:E22. http://www.aapspharmscitech.org.CrossRefGoogle Scholar
  9. 9.
    Park CR, Munday DL. Evaluation of selected polysaccharide excipients in buccoadhesive tablets for sustained release of nicotine. Drug Dev Ind Pharm. 2004;30:609–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Nagai T, Konishi R. Buccal/gingival drug delivery systems. J Control Release. 1987;6:353–60.CrossRefGoogle Scholar
  11. 11.
    Junginger HE, Hoogstraate JA, Verhoef JC. Recent advances in buccal drug delivery and absorption: in vitro and In vivo studies. J Control Release. 1999;62:149–59.CrossRefPubMedGoogle Scholar
  12. 12.
    Pramodkumar TM, Desai KGh, Shivakumar HG. Buccal permeation enhancers. Ind J Pharm Edu. 2002;36:147–51.Google Scholar
  13. 13.
    Munasur P, Pillay V, Chetty DJ, Govender T. Statistical optimization of the mucoadhesivity and characterization of multipolymeric propranolol matrices for buccal therapy. Int J Pharm. 2006;323:43–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Sohi H, Khar RK, Singh S. Development of controlled release tablets of anti-migraine agent. Proceeding of the 31st Annual Meeting and Exposition of the Controlled Release Society. 2004, June 12–16, Honolulu, Hawaii, USA; 290Google Scholar
  15. 15.
    Jug M, Becirevic-Lacan M. Influence of hydroxypropyl-β-cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur J Pharm Sci. 2004;21:251–260.CrossRefPubMedGoogle Scholar
  16. 16.
    Bottenberg P, Cleymaet R, Muynck CD, Remon JP, Coomans D, Slop D. Development and testing of bio-adhesive, fluoride-containing slow release tablets for oral use. J Pharm Pharmacol. 1991;43:457–64.PubMedGoogle Scholar
  17. 17.
    Parodi B, Russo E, Caviglioli G, Cafaggi S, Bignardi G. Development and characterization of a buccoadhesive dosage form of oxycodone hydrochloride. Drug Dev Ind Pharm. 1996;22:445–50.CrossRefGoogle Scholar
  18. 18.
    Okamoto H, Taguchi H, Iida K, Danjo K. Development of polymer film dosage forms of lidocaine for buccal administration I. penetration rate and release rate. J Control Release. 2001;77:253–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Sandri G, Rossi S, Bonferoni MC, Ferrari F, Zambito Y, Colo GD, et al. Buccal penetration enhancement properties of N-trimethyl chitosan: influence of quaternization degree on absorption of a high molecular weight molecule. Int J Pharm. 2005;297:146–55.PubMedGoogle Scholar
  20. 20.
    Ceschel GC, Bergamante V, Calabrese V, Biserni S. Design and evaluation in vitro of controlled release mucoadhesive tablets containing chlorhexidene. Drug Dev Ind Pharm. 2006;32:53–61.CrossRefGoogle Scholar
  21. 21.
    Sandri G, Rossi S, Ferrari F, Bonferoni MC, Muzzarelli C, Caramella C. Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur J Pharm Sci. 2004;21:351–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Patel VM, Prajapati BG, Patel MM. Design and characterization of chitosan-containing mucoadhesive buccal patches of propranolol hydrochloride. Acta Pharm. 2007;57:61–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Jain SK, Jain NK, Gupta Y, Jain A, Jain D, Chaurasia M. mucoadhesive chitosan microspheres for non-invasive and improved nasal delivery of insulin. Ind J Pharm Sci. 2007;69:498–504.CrossRefGoogle Scholar
  24. 24.
    Eouani C, Piccerelle Ph, Prinderre P, Bourret E, Joachim J. In vitro comparative study of buccal mucoadhesive performance of different polymeric films. Eur J Pharm Biopharm. 2001;52:45–55.CrossRefPubMedGoogle Scholar
  25. 25.
    Feng-Qian LI, Jin-Hong HU, Deng JX, Su H, Xu S, Liu JY. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int J Pharm. 2006;324:152–7.CrossRefGoogle Scholar
  26. 26.
    Obaidat AA, Obaidat RM. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm. 2001;52:231–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–11.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Nisreen Hassan
    • 1
  • R. K. Khar
    • 1
  • Mushir Ali
    • 1
  • Javed Ali
    • 1
  1. 1.Department of Pharmaceutics, Faculty of PharmacyJamia Hamdard, Hamdard NagarNew DelhiIndia

Personalised recommendations